New hope for breast cancer patients: extra targeted drug may clear remaining tumors
NCT ID NCT07589699
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding 4 cycles of the targeted drug trastuzumab rezetecan (T-DXh) can eliminate residual cancer in HER2-positive breast cancer patients who still have disease after standard chemotherapy. About 59 adults will receive the drug before surgery. The main goal is to see how many achieve a complete response (no cancer found in breast or lymph nodes).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trastuzumab rezetecan (T-DXh), a targeted drug that delivers chemotherapy directly to HER2-positive cancer cells
- What this could lead to
- If successful, this could offer a more effective neoadjuvant option for patients who don't fully respond to standard therapy, potentially reducing recurrence risk.
- What could go wrong
- This is a small, early-phase study (59 participants) without a control group, so results may not be generalizable. The drug can cause side effects like low blood counts or lung inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?